Product Description
Mechanisms of Action: NRT Inhibitor,Nucleic Acid Synthesis Inhibitor,NRF2 Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PharmaKing
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PMK-N01GI1-P3 | P3 |
Completed |
Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2022-09-02 |
47% |